FKBP12 is best known as the target of the widely used immunosuppressive drug FK506 but may also play a role in neuronal survival. Nonimmunosuppressive ligands of FKBP12 have been shown to have neuroprotective and neuroregenerative activity both in vitro and in vivo, stimulating interest in the development of high-throughput screens to rapidly identify novel ligands. FKBP12 was expressed as a His6-fusion in bacteria and purified by metal ion affinity and gel filtration chromatography. A high-throughput fluorescence polarization assay was developed to identify novel ligands of FKBP12. Dissociation constant values of known FKBP12 ligands measured by the new method agreed closely with Ki values obtained by assaying inhibition of the rotamase activity of the enzyme. The fluorescence polarization assay is rapid, robust, and inexpensive and does not generate radioactive waste. It is very well suited for high-throughput screening efforts.
References
1.
1. Fretz H, Albers MW, Galat A, Standaert RF, Lane WS, Burakoff SJ, et al: Rapamycin and FK506 binding proteins (immunophilins). J Am Chem Soc1991;113:1409-1411.
2.
2. Brillantes AB, Ondrias K, Scott A, Kobrinsky E, Ondriasova E, Moschella MC, et al: Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein. Cell1994;77:513-523.
4. Wang T, Donahoe PK, Zervos AS: Specific interaction of type I receptors of the TGF-beta family with the immunophilin FKBP-12. Science1994;265:674-676.
5.
5. Lyons WE, George EB, Dawson TM, Steiner JP: Immunosuppressant FK506 promotes neurite outgrowth in cultures of PC12 cells and sensory ganglia. Proc Natl Acad Sci USA1994;91:3191-3195.
6.
6. Steiner JP, Dawson TM, Fotuhi M, Glatt CE, Snowman AM, Cohen N, et al: High brain densities of the immunophilin FKBP colocalized with calcineurin. Nature1992;358:584-587.
7.
7. Lyons WE, Steiner JP, Snyder SH, Dawson TM: Neuronal regeneration enhances the expression of the immunophilin FKBP-12. J Neurosci1995;15:2985-2994.
9. Li W, Handschumacher RE: Specific interaction of the cyclophilin-cyclosporin complex with the B subunit of calcineurin. J Biol Chem1993;268:14040-14044.
10.
10. Van Duyne GD, Standaert RF, Karplus PA, Schreiber SL, Clardy J: Atomic structure of FKBP-FK506, an immunophilin-immunosuppressant complex. Science1991;252:839-842.
11.
11. Ross DT, Valentine HL, Guo H, Hamilton GS, Huang W, Suzdak PD, et al: Novel neuroimmunophilin ligands for FKBP-12 possess potent neurotrophic activity in the mouse MPTP model of Parkinson’s disease. Society for Neuroscience1996:297.14.
12.
12. Steiner JP, Connolly MA, Valentine HI, Hamilton GS, Dawson TM, Hester L, et al: Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A. Nature Med1997;3:421-428.
13.
13. Gold BG, Storm-Dickerson T, Austin DR, Katoh K: FK506, an immunosuppressent, increases functional recovery and axonal regeneration in the rat following axotomy of the sciatic nerve. Society for Neuroscience1993:543.18.
14.
14. Gold BG, Zeleny-Pooley M, Wang M-S, Chaturvedi P, Armistead DM: A nonimmunosuppressant FKBP-12 ligand increases nerve regeneration. Exp Neurol1997;147:269-278.
15.
15. Kofron JL, Kuzmic P, Kishore V, Colon-Bonilla E, Rich DH: Determination of kinetic constants for peptidyl-prolyl cis-trans isomerases by an improved spectrophotometric assay. Biochemistry1991;30:6127-6134.
16.
16. Fesik SW, Neri P: Multidimensional NMR studies of immunosuppressant/immunophilin complexes. In Clore G (ed): NMR of Proteins. Boca Raton, FL: CRC, 1993:92-133.
17.
17. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW: Discovering high-affinity ligands for proteins: SAR by NMR. Science1996;274:1531-1534.
18.
18. Graziani F, Aldegheri L, Terstappen GC: High throughput scintillation proximity assay for the identification of FKBP-12 ligands. J Biomol Screening1999;4:3-7.
19.
19. Weber G: Rotational Brownian motion and polarization of the fluorescence in solutions. Adv Protein Chem1953;8:415.
20.
20. Dandliker WB, Feigen GA: Quantification of the antigen-antibody reaction by the polarization of fluorescence. Biochem Biophys Res Commun1961;5:299-304.
21.
21. Dubowchik GM, Ditta JL, Bollini S, Herbst J, Vinitsky A: Fluoresceinated FKBP12 ligands for a high-throughput fluorescence polarization assay. Bioorg Med Chem Lett2000;20:559-562.
23. Holt DA, Luengo JI, Yamashita DS, Oh HJ, Konialian AL, Yen HK, et al: Design, synthesis, and kinetic evaluation of high-affinity FKBP ligands and the X-ray crystal structures of their complexes with FKBP12. JAm Chem Soc1993;115:9925-9938.
24.
24. Munson PJ, Rodbard D: Correction of Cheng Prousoff equation. Journal of Receptor Research1988;8:533-546.
25.
25. Hamilton GS, Steiner JP: Neuroimmunophilin ligands and novel therapeutics for the treatment of degenerative disorders of the nervous system. Curr Pharm Des1997;3:405-428.
26.
26. Owicki JC: Fluorescence polarization and anisotropy in high throughput screening: perspectives and primer. J Biomol Screen2000;5:297-306.
27.
27. Rajkowski KM, Cittanova N: Corrected equations for the calculation of protein-ligand binding results from fluorescence polarization data. J Theor Biol1981;93:691-696.
28.
28. Steiner JP, Hamilton GS, Ross DT, Valentine HL, Guo HZ, Connolly MA, et al: Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Proc Natl Acad Sci USA1997;94:2019-2024.
29.
29. Bocquet AL, Fuks G, Grimee B, Talaga R, Daliers P, Klitgaard J: Failure of GPI compounds to display neurotrophic activity in vitro and in vivo. Eur J Pharmacol2001;415:173-180.
